AKT1 and hepatocellular carcinoma: CuB may enhance methionine metabolism, tyrosine metabolism, and lipid metabolism abnormalities by controlling methionine and tyrosine content and thereby treat AKT/c-Met-induced HCC, according to the experimental findings.